Skip to Main Content

Try STAT+ TODAY

duchenne muscular dystrophy

Most Read

Biotech Adam Feuerstein

STAT Plus: Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

Pharmalot Ed Silverman

FDA emails show how upset some officials were over the Sarepta approval

Health Shayla Love

Does the FDA have a high enough standard for drug approvals?

Pharmalot Ed Silverman

Doctors expect to prescribe Sarepta’s DMD drug despite insurance concerns

Pharmalot Ed Silverman

FDA commissioner calls for Sarepta drug study to be retracted

Health Jeffery DelViscio

Watch: For two brothers with Duchenne, an FDA drug approval brings joy and relief

Pharmalot Ed Silverman

Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says

Biotech Damian Garde

Did the FDA set ‘a dangerous precedent’ with its latest drug approval?

All Coverage

First Opinion David Gortler

FDA’s drug approval process should be based on science, not public opinion

Pharmalot Ed Silverman

FDA delays decision on whether to approve Sarepta drug for Duchenne

advertisement

Pharmalot Ed Silverman

Senators urge FDA to approve Sarepta drug for Duchenne

First Opinion Marco Rubio

Marco Rubio to FDA: Don’t yank hope from dying children

Pharmalot Ed Silverman

FDA panel votes against Sarepta’s drug for Duchenne muscular dystrophy

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: FDA panel reviewing Duchenne muscular dystrophy drug

Pharmalot Ed Silverman

FDA review raises fresh doubts that Sarepta DMD drug will be approved

Pharmalot Ed Silverman

FDA urged to approve Sarepta DMD drug by dozens of medical experts

Pharmalot Ed Silverman

FDA rejects application for Duchenne drug, rattling investors and parents

Pharmalot Ed Silverman

FDA delays decision on Duchenne drug but accepts info from Sarepta

Pharmalot Ed Silverman

Why the FDA shouldn’t bow to parental pressure over Duchenne drug

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: ‘Misleading’ sedative video, Duchenne drug meeting delayed

Pharmalot Ed Silverman

FDA staff is sour on Sarepta drug for Duchenne muscular dystrophy

Pharmalot Ed Silverman

FDA rejects drug for Duchenne muscular dystrophy

In the Lab Melissa Bailey

Gene therapy treats Duchenne muscular dystrophy in mice

Pharmalot Ed Silverman

FDA panel casts doubt on Duchenne drug

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: CVS covers new cholesterol drug, FDA Duchenne hearing